Effects of Ido1 on mouse decidualization

被引:0
|
作者
D.-D. Li
Y.-H. Yin
J.-Y. Wu
Z.-Q. Yang
H. Cao
Q.-L. Zhang
B. Guo
Z.-P. Yue
机构
[1] Jilin University,College of Veterinary Medicine
[2] Guizhou Minzu University,Department of Laboratory Medicine
[3] General Hospital of Jinan Military Region of PLA,undefined
来源
Molecular Biology | 2015年 / 49卷
关键词
Ido1; decidualization; uterus; mouse;
D O I
暂无
中图分类号
学科分类号
摘要
Indoleamine 2,3-dioxygenase 1 (Ido1) is a rate-limiting enzyme which converts the essential amino acid tryptophan to kynurenine. The aim of this study was to investigate the expression and regulation of Ido1 in mouse uterus during decidualization. The results showed that Ido1 mRNA expression gradually increased from day 1 to 4 of pregnancy and reached the peak level on day 4. On days 5–8 of pregnancy, a low level of Ido1 expression was observed in the uteri. Simultaneously, Ido1 mRNA was also lowly expressed in the decidualized uterus and the stromal cells treated with 8-Br-cAMP. Under in vitro decidualization, the expression of Ido1 mRNA gradually declined. Further studies found that overexpression of Ido1 can inhibit the expression of decidualization marker genes PRL, IGFBP1 and Dtprp under in vitro decidualization while inhibition of Ido1 with L-1-MT can induce the expression of these marker genes. Ido1 can prevent uterine stromal cells proliferation and enhance the expression of the Bax gene and increase the Bax/Bcl2 ratio under in vitro decidualization. Additionally, Ido1 can also modulate the expression of the MMP2 gene. In the uterine stromal cells, estrogen and progesterone can stimulate the expression of Ido1. These data indicate that Ido1 may play an important role during mouse decidualization and may be regulated by estrogen and progesterone in the uterine stromal cells.
引用
收藏
页码:581 / 588
页数:7
相关论文
共 50 条
  • [41] Identifying Antidepressant Effects of Brain-Derived Neurotrophic Factor and IDO1 in the Mouse Model Based on RNA-Seq Data
    Ren, Jing
    Li, Chenyang
    Wei, Songren
    He, Yanjun
    Huang, Peng
    Xu, Jiangping
    FRONTIERS IN GENETICS, 2022, 13
  • [42] Treatment of IDO1 and TDO2 positive tumors with a kynurenine-degrading enzyme: A highly differentiated approach from IDO1 inhibition
    Coma, Silvia
    Cavanaugh, Jillian
    Nolan, James
    Tchaicha, Jeremy
    McGovern, Karen
    Stone, Everett
    Blazeck, John
    Lamb, Candice
    Georgiou, George
    Manfredi, Mark G.
    Zhang, Michelle
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [43] Indoleamine 2,3-Dioxygenase 1 (Ido1) Is Involved in the Control of Mouse Caput Epididymis Immune Environment
    Jrad-Lamine, Aicha
    Henry-Berger, Joelle
    Damon-Soubeyrand, Christelle
    Saez, Fabrice
    Kocer, Ayhan
    Janny, Laurent
    Pons-Rejraji, Hanae
    Munn, David H.
    Mellor, Andrew L.
    Gharbi, Najoua
    Cadet, Remi
    Guiton, Rachel
    Aitken, Robert J.
    Drevet, Joel R.
    PLOS ONE, 2013, 8 (06):
  • [44] Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1
    Peng, Yi-Hui
    Ueng, Shau-Hua
    Tseng, Chen-Tso
    Hung, Ming-Shiu
    Song, Jen-Shin
    Wu, Jian-Sung
    Liao, Fang-Yu
    Fan, Yu-Shiou
    Wu, Mine-Hsine
    Hsiao, Wen-Chi
    Hsueh, Ching-Cheng
    Lin, Shu-Yu
    Cheng, Chia-Yi
    Tu, Chih-Hsiang
    Lee, Lung-Chun
    Cheng, Ming-Fu
    Shia, Kak-Shan
    Shih, Chuan
    Wu, Su-Ying
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (01) : 282 - 293
  • [45] Identification and characterization of the IDO1 inhibitor LY3381916
    Dorsey, Frank C.
    Benhadji, Karim A.
    Sams, Lillian L.
    Young, Debra A.
    Schindler, John F.
    Huss, Karen L.
    Nikolayev, Alexander
    Carpenito, Carmine
    Clawson, David
    Jones, Bonita
    Faber, Andrew L.
    Thomas, James E.
    Haney, Steven A.
    Zhao, Gaiying
    McMillen, William T.
    Smeal, Tod
    Sall, Daniel J.
    Kalos, Michael D.
    Geeganage, Sandaruwan
    Henry, James R.
    CANCER RESEARCH, 2018, 78 (13)
  • [46] Targeting the IDO1 pathway in cancer: from bench to bedside
    Ming Liu
    Xu Wang
    Lei Wang
    Xiaodong Ma
    Zhaojian Gong
    Shanshan Zhang
    Yong Li
    Journal of Hematology & Oncology, 11
  • [47] An adverse tumor-protective effect of IDO1 inhibition
    Kenski, Juliana C. N.
    Huang, Xinyao
    Vredevoogd, David W.
    de Bruijn, Beaunelle
    Traets, Joleen J. H.
    Ibanez-Molero, Sofia
    Schieven, Sebastiaan M.
    van Vliet, Alex
    Krijgsman, Oscar
    Kuilman, Thomas
    Pozniak, Joanna
    Loayza-Puch, Fabricio
    Terry, Alexandra M.
    Mueller, Judith
    Logtenberg, Meike E. W.
    de Bruijn, Marjolein
    Levy, Pierre
    Korner, Pierre-Rene
    Goding, Colin R.
    Schumacher, Ton N.
    Marine, Jean-Christophe
    Agami, Reuven
    Peeper, Daniel S.
    CELL REPORTS MEDICINE, 2023, 4 (02)
  • [48] Expression of IDO1 is regulated via Ras signaling pathways
    Lee, Eunji
    He, Felicia
    Choi, Byeong Hyeok
    Dai, Wei
    FASEB JOURNAL, 2022, 36
  • [49] Regulation of IDO1 expression and the kynurenine pathway in synovial fibroblasts
    Municho, Cristina
    Ergueta, Sandra
    Usategui, Alicia
    Del Rey, Manuel J.
    Pablos, Jose L.
    Criado, Gabriel
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [50] Targeting the IDO1 pathway in cancer: from bench to bedside
    Liu, Ming
    Wang, Xu
    Wang, Lei
    Ma, Xiaodong
    Gong, Zhaojian
    Zhang, Shanshan
    Li, Yong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11